Estimated OS and EFS for whole cohort and IEI subgroups
| Group . | N . | OS . | N . | EFS . | ||||
|---|---|---|---|---|---|---|---|---|
| 6 mo (95% CI) . | 1 y (95% CI) . | 5 y (95% CI) . | 6 mo (95% CI) . | 1 y (95% CI) . | 5 y (95% CI) . | |||
| Whole cohort | 329 | 83% (79-87) | 78% (74-83) | 71% (66-76) | 319 | 70% (65-75) | 65% (60-71) | 62% (56-67) |
| CID | 163 | 80% (74-86) | 76% (69-83) | 68% (61-76) | 157 | 68% (61-75) | 64% (56-71) | 58% (50-67) |
| PD∗ | 127 | 93% (88-97) | 87% (81-93) | 78% (71-86) | 123 | 77% (70-85) | 72% (64-80) | 69% (61-77) |
| CGD alone† | 83 | 92% (86-98%) | 83% (75-91%) | 77% (67-86%) | 80 | 74% (64-83%) | 69% (59-79%) | 67% (57-78%) |
| PAD‡ | 39 | 64% (49-79) | 59% (44-74) | 59% (44-74) | 39 | 54% (38-69) | 51% (36-67) | 51% (36-67) |
| CVID alone§ | 27 | 56% (37-74) | 48% (29-67) | 48% (29-67) | 27 | 44% (26-63) | 41% (22-59) | 41% (22-59) |
| Group . | N . | OS . | N . | EFS . | ||||
|---|---|---|---|---|---|---|---|---|
| 6 mo (95% CI) . | 1 y (95% CI) . | 5 y (95% CI) . | 6 mo (95% CI) . | 1 y (95% CI) . | 5 y (95% CI) . | |||
| Whole cohort | 329 | 83% (79-87) | 78% (74-83) | 71% (66-76) | 319 | 70% (65-75) | 65% (60-71) | 62% (56-67) |
| CID | 163 | 80% (74-86) | 76% (69-83) | 68% (61-76) | 157 | 68% (61-75) | 64% (56-71) | 58% (50-67) |
| PD∗ | 127 | 93% (88-97) | 87% (81-93) | 78% (71-86) | 123 | 77% (70-85) | 72% (64-80) | 69% (61-77) |
| CGD alone† | 83 | 92% (86-98%) | 83% (75-91%) | 77% (67-86%) | 80 | 74% (64-83%) | 69% (59-79%) | 67% (57-78%) |
| PAD‡ | 39 | 64% (49-79) | 59% (44-74) | 59% (44-74) | 39 | 54% (38-69) | 51% (36-67) | 51% (36-67) |
| CVID alone§ | 27 | 56% (37-74) | 48% (29-67) | 48% (29-67) | 27 | 44% (26-63) | 41% (22-59) | 41% (22-59) |